

Product datasheet for **TR303805**

KCNQ2 Human shRNA Plasmid Kit (Locus ID 3785)

Product data:

Product Type:	shRNA Plasmids
Product Name:	KCNQ2 Human shRNA Plasmid Kit (Locus ID 3785)
Locus ID:	3785
Synonyms:	BFNC; DEE7; EBN; EBN1; ENB1; HNSPC; KCNA11; KV7.2
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	KCNQ2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 3785). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	BC000699 , NM_004518 , NM_172106 , NM_172107 , NM_172108 , NM_172109 , NM_172107.1 , NM_172107.2 , NM_172107.3 , NM_172106.1 , NM_172106.2 , NM_172109.1 , NM_172109.2 , NM_004518.1 , NM_004518.2 , NM_004518.3 , NM_004518.4 , NM_004518.5 , NM_172108.1 , NM_172108.2 , NM_172108.4 , BC020384 , BC127262 , BC146294 , NM_172109.3 , NM_172106.3 , NM_004518.6 , NM_172108.5 , NM_172107.4
UniProt ID:	O43526
Summary:	The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).